癌症免疫疗法，第3部分：挑战与未来趋势。
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
作者信息
Ventola C Lee
出版信息
P T. 2017 Aug;42(8):514-521.
Abstract
Despite dramatic breakthroughs, obstacles remain for the field of immunotherapy in cancer. These include the inability to predict treatment efficacy and patient response; the need for improved biomarkers; the development of resistance to immunotherapies; the lack of optimized clinical study designs; and high costs. Are solutions in sight?
摘要
尽管取得了重大突破，但癌症免疫治疗领域仍存在障碍。这些障碍包括无法预测治疗效果和患者反应；需要改进生物标志物；对免疫疗法产生耐药性；缺乏优化的临床研究设计；以及成本高昂。有解决办法了吗？
相似文献
1
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
P T. 2017 Aug;42(8):514-521.
2
Circulating biomarkers predictive of tumor response to cancer immunotherapy.
Expert Rev Mol Diagn. 2019 Oct;19(10):895-904. doi: 10.1080/14737159.2019.1659728. Epub 2019 Sep 10.
3
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.
4
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
J Immunother Cancer. 2016 Nov 15;4:76. doi: 10.1186/s40425-016-0178-1. eCollection 2016.
5
Canine cancer immunotherapy studies: linking mouse and human.
J Immunother Cancer. 2016 Dec 20;4:97. doi: 10.1186/s40425-016-0200-7. eCollection 2016.
6
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016.
7
Melanoma Immunotherapy: Next-Generation Biomarkers.
Front Oncol. 2018 May 29;8:178. doi: 10.3389/fonc.2018.00178. eCollection 2018.
8
Improving the efficacy of cancer immunotherapy.
Eur J Cancer. 2009 May;45(8):1424-31. doi: 10.1016/j.ejca.2008.12.017. Epub 2009 Jan 21.
9
Immunoengineering with biomaterials for enhanced cancer immunotherapy.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506. doi: 10.1002/wnan.1506. Epub 2018 Jan 14.
10
Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.
Adv Drug Deliv Rev. 2019 Feb 15;141:3-22. doi: 10.1016/j.addr.2018.01.005. Epub 2018 Jan 12.
引用本文的文献
1
Disparities in the Receipt of Immunotherapy for Patients With Head and Neck Mucosal Melanoma.
Laryngoscope Investig Otolaryngol. 2025 Aug 7;10(4):e70232. doi: 10.1002/lio2.70232. eCollection 2025 Aug.
2
Gut microbiota shapes cancer immunotherapy responses.
NPJ Biofilms Microbiomes. 2025 Jul 25;11(1):143. doi: 10.1038/s41522-025-00786-8.
3
Optimizing Oncology Generic Medication Selection in the Gulf Region: Expert Consensus and MCDA Tool Development.
J Health Econ Outcomes Res. 2025 Jul 18;12(2):21-26. doi: 10.36469/001c.140955. eCollection 2025.
4
Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.
Sci Rep. 2025 Jul 1;15(1):21570. doi: 10.1038/s41598-025-95713-4.
5
Optogenetic control of T cells for immunomodulation.
Essays Biochem. 2025 Jun 23. doi: 10.1042/EBC20253014.
6
The immunopeptidome of colon cancer cells treated with topoisomerase inhibiting drug reveals differential as well as common endogenous protein sampling and display of MHC I-associated peptides.
Mol Cell Oncol. 2025 Mar 3;12(1):2471640. doi: 10.1080/23723556.2025.2471640. eCollection 2025.
7
A novel T-cell proliferation-related model for predicting the prognosis of head and neck squamous cell carcinoma.
Medicine (Baltimore). 2025 Feb 28;104(9):e41657. doi: 10.1097/MD.0000000000041657.
8
Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells.
Front Oncol. 2025 Jan 22;14:1524651. doi: 10.3389/fonc.2024.1524651. eCollection 2024.
9
Integrating AI into Cancer Immunotherapy-A Narrative Review of Current Applications and Future Directions.
Diseases. 2025 Jan 20;13(1):24. doi: 10.3390/diseases13010024.
10
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.
Korean J Clin Oncol. 2024 Dec;20(2):51-73. doi: 10.14216/kjco.24009. Epub 2024 Dec 31.
本文引用的文献
1
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
2
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
Cancer Treat Rev. 2016 Jul;48:20-4. doi: 10.1016/j.ctrv.2016.06.002. Epub 2016 Jun 7.
3
Current Challenges in Cancer Treatment.
Clin Ther. 2016 Jul;38(7):1551-66. doi: 10.1016/j.clinthera.2016.03.026. Epub 2016 May 2.
4
Cancer immunoprevention.
Curr Opin Immunol. 2016 Apr;39:52-8. doi: 10.1016/j.coi.2016.01.002. Epub 2016 Jan 19.
5
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016.
6
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.
7
Cancer immunology for the clinician.
Clin Adv Hematol Oncol. 2015 May;13(5):299-306.
8
Cancer immunotherapy: harnessing the immune system to battle cancer.
J Clin Invest. 2015 Sep;125(9):3335-7. doi: 10.1172/JCI83871. Epub 2015 Sep 1.
9
Cancer and the Immune System: Basic Concepts and Targets for Intervention.
Semin Oncol. 2015 Aug;42(4):523-38. doi: 10.1053/j.seminoncol.2015.05.003. Epub 2015 Jun 3.
10
Cancer Immunotherapies--and Their Cost--Take Center Stage at ASCO's 2015 Annual Meeting.
Manag Care. 2015 Jul;24(7):30-2.
Zotero 插件